Table 3 Logistic analysis on factors associated with the development of skin disorders
Factors | Occurrence of skin disorders | Univariate logistic analysis | Multivariate logistic analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Yes (n = 10) | No (n = 49) | OR | 95% CI | P | OR | 95% CI | P | ||||
n | % | n | % | ||||||||
Use of hydromorphone (non-use of morphine) | 1 | 10.0 | 26 | 53.1 | 0.10 | 0.01–0.99 | 0.034 | 0.04 | 0.003–0.48 | 0.012 | |
Age ≥ 75 | 2 | 20.0 | 7 | 14.3 | 2.20 | 0.36–18.37 | 0.391 | – | – | – | |
Male | 4 | 40.0 | 25 | 51.0 | 1.04 | 0.27–4.06 | 0.953 | – | – | – | |
Performance status 4 | 9 | 90.0 | 40 | 81.6 | 1.76 | 0.19–15.86 | 0.616 | – | – | – | |
Body mass index ≥ 25 | 2 | 20.0 | 8 | 16.3 | 1.28 | 0.23–7.19 | 0.778 | – | – | – | |
Concomitant steroid use | 7 | 70.0 | 32 | 65.3 | 1.24 | 0.28–5.42 | 0.775 | 0.30 | 0.04–2.25 | 0.244 | |
Concomitant non-opioid analgesics use | 5 | 50.0 | 21 | 42.9 | 1.33 | 0.39–5.21 | 0.479 | 0.93 | 0.16–5.63 | 0.943 | |
Concomitant anti-histamine use | 1 | 10.0 | 10 | 20.4 | 0.43 | 0.05–3.83 | 0.452 | 0.51 | 0.03–7.56 | 0.623 | |
Dilution with saline solution | 1 | 10.0 | 5 | 10.2 | 0.99 | 0.10–9.45 | 0.992 | – | – | – | |
Starting flow rate ≥ 0.5 mL/h | 0 | 0 | 2 | 4.1 | – | – | – | – | – | – | |
Daily dosage (morphine equivalent ≥ 60 mg/day) | 9 | 90.0 | 41 | 83.7 | 1.76 | 0.19–15.86 | 0.616 | – | – | – | |
Administration period ≥ 28 day | 5 | 50.0 | 8 | 16.3 | 5.13 | 1.20-21.91 | 0.028 | 18.16 | 2.22–148.60 | 0.007 | |